초록 ▼

The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a

The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a preterm infant using preterm infant formulas comprising mixtures of carotenoids.

대표청구항 ▼

1. A method of modulating inflammation in an infant having inflammation characterized by an elevated plasma level of C-reactive protein, the method comprising: administering to the infant having inflammation characterized by an elevated plasma level of C-reactive protein a preterm infant formula com

1. A method of modulating inflammation in an infant having inflammation characterized by an elevated plasma level of C-reactive protein, the method comprising: administering to the infant having inflammation characterized by an elevated plasma level of C-reactive protein a preterm infant formula comprising about 75 μg/L to about 500 μg/L of lutein, about 60 μg/L to about 500 μg/L of lycopene, and about 85 μg/L to about 500 μg/L of beta-carotene. 2. The method of claim 1, wherein the inflammation characterized by an elevated plasma level of C-reactive protein is due to infection. 3. The method of claim 1, wherein the inflammation is decreased by decreasing the plasma level of C-reactive protein in the infant. 4. The method of claim 1, wherein the preterm infant formula is administered to the infant until the plasma level of C-reactive protein in the infant has decreased. 5. The method of claim 1, wherein the inflammation characterized by an elevated plasma level of C-reactive protein is skin inflammation. 6. The method of claim 1, wherein the infant is a preterm infant, and the preterm infant formula is administered to the preterm infant until the preterm infant reaches about 40 weeks post-menstrual age. 7. The method of claim 1, wherein the infant is a preterm infant, and the preterm infant formula is administered to the preterm infant until the preterm infant reaches about 50 weeks post-menstrual age. 8. The method of claim 1, wherein the preterm infant formula comprises about 200 μg/L to about 250 μg/L of lutein, about 100 μg/L to about 150 μg/L of lycopene, and about 200 μg/L to about 250 μg/L of beta-carotene. 9. The method of claim 8, wherein the preterm infant formula comprises about 212 μg/L of lutein, about 143 μg/L of lycopene, and about 220 μg/L of beta-carotene. 10. The method of claim 1, wherein the preterm infant formula provides to the infant about 22 μg/kg/day to about 150 μg/kg/day of lutein, about 18 μg/kg/day to about 150 μg/kg/day of lycopene, and about 26 μg/kg/day to about 150 μg/kg/day of beta-carotene. 11. The method of claim 1, wherein the preterm infant formula further comprises about 5 μg/L to about 50 μg/L of zeaxanthin. 12. The method of claim 1, wherein the preterm infant formula further comprises at least one of vitamins, minerals, carbohydrate, lipid, and protein. 13. The method of claim 1, wherein the preterm infant formula comprises, as a percentage of total calories, about 35% to about 50% carbohydrate, about 30% to about 60% lipid, and about 7.5% to about 25% protein. 14. A method of modulating the plasma level of C-reactive protein in an infant having an elevated plasma level of C-reactive protein, the method comprising: administering to the infant having an elevated plasma level of C-reactive protein a preterm infant formula comprising about 75 μg/L to about 500 μg/L of lutein, about 60 μg/L to about 500 μg/L of lycopene, and about 85 μg/L to about 500 μg/L of beta-carotene. 15. The method of claim 14, wherein the elevated plasma level of C-reactive protein is due to infection. 16. The method of claim 14, wherein the infant is a preterm infant, and the preterm infant formula is administered to the preterm infant until the preterm infant reaches about 40 weeks post-menstrual age. 17. The method of claim 14, wherein the infant is a preterm infant, and the preterm infant formula is administered to the preterm infant until the preterm infant reaches about 50 weeks post-menstrual age. 18. The method of claim 14, wherein the preterm infant formula comprises about 200 μg/L to about 250 μg/L of lutein, about 100 μg/L to about 150 μg/L of lycopene, and about 200 μg/L to about 250 μg/L of beta-carotene. 19. The method of claim 18, wherein the preterm infant formula comprises about 212 μg/L of lutein, about 143 μg/L of lycopene, and about 220 μg/L of beta-carotene. 20. The method of claim 14, wherein the preterm infant formula provides to the infant about 22 μg/kg/day to about 150 μg/kg/day of lutein, about 18 μg/kg/day to about 150 μg/kg/day of lycopene, and about 26 μg/kg/day to about 150 μg/kg/day of beta-carotene. 21. The method of claim 14, wherein the preterm infant formula further comprises about 5 μg/L to about 50 μg/L of zeaxanthin.